Floatz logo

Amiloride

Hormone Receptor Positive Breast Carcinoma

Laura Huppert, MD, BASmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

11 Active assets in the Hormone Receptor Positive Breast Carcinoma cohort.

Asset / SponsorPhaseRating
Trastuzumab Deruxtecan
National Cancer Institute (NCI)
Phase 2B
Fruquintinib
Immunitas Therapeutics
Phase 1/2CCC
ds-8201a
MedSIR
Phase 2CCC
FLUDEOXYGLUCOSE
University of Washington
Phase 2CCC
Palazestrant
Olema Pharmaceuticals, Inc.
Phase 1/2CCC

View all 16 →

Same molecule, other indications

Amiloride is also rated in:

nephrotic syndromeDormant
B
Indicative ·
60 / 100
View asset →
Sodium RetentionDormant
B
Indicative ·
60 / 100
View asset →
bipolar disorderDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →